PDCD1 and cancer: Based on these results, we conclude that both PD-1 and PD-L1 analysed in various lymphocyte T and B subsets may have applications as biomarkers of COVID-19 severity in addition to its roles in cancer therapy, as previously proposed [34], and may provide a basis for the use of exhaustion reversal agents to limit the progression of the COVID-19 in the severe stages.